Css LLC Gilead Sciences, Inc. Transaction History

Css LLC

$928 Million
Q3 2025

A detailed history of Css LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Css LLC holds 8,060 shares of GILD stock, worth $1 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

8,060

Previous 8,050 0.12%

Holding current value

$1 Million

Previous $892,000 0.22%

% of portfolio

0.1%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$108.22 - $120.47 $1,082 - $1,204	10 Added 0.12%	8,060 $894,000
Q2 2025 Aug 14, 2025	SELL	$96.91 - $113.0 $617,413 - $719,923	-6,371 Reduced 44.18%	8,050 $892,000
Q1 2025 May 15, 2025	SELL	$89.14 - $117.41 $385,976 - $508,385	-4,330 Reduced 23.09%	14,421 $1.62 Million
Q4 2024 Feb 14, 2025	SELL	$83.95 - $97.9 $41,975 - $48,950	-500 Reduced 2.6%	18,751 $1.73 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $334,695 - $386,264	5,300 Added 37.99%	19,251 $1.32 Million

Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $178,950 - $218,225	2,500 Added 21.83%	13,951 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $260,181 - $295,052	3,551 Added 44.95%	11,451 $927,000
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $44,364 - $48,402	-600 Reduced 7.06%	7,900 $592,000
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $76,010 - $86,700	1,000 Added 13.33%	8,500 $655,000
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $579,825 - $660,600	7,500 New	7,500 $622,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $3.07 Million - $3.56 Million	-42,372 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $2.65 Million - $3.4 Million	42,372 New	42,372 $3.17 Million

Others Institutions Holding GILD

# of Institutions

2,367

Shares Held

1.01B

Call Options Held

8.58M

Put Options Held

7.35M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $156B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.

Account